The Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency (EMA) will keep reviewing reports on pericarditis and myocarditis following vaccination with Johnson & Johnson's covid-19 vaccine. PRAC concludes that more data and investigation will be needed in order to assess whether there is a documented connection between cause and effect, according to the Danish Medicines Agency (DMA).
PRAC has further stated that it is closely monitoring thrombosis with thrombocytopenia syndrome in connection with the vaccine, but has no updates on this at the moment.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Rumored GN purchase unlikely but not impossible, say analysts
A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.
EMA begins analyzing Bavarian Nordic's vaccine against monkeypox
Prior to deciding on a shared European vaccine supply purchase, the European Medicines Agency has begun analyzing the Danish firm’s smallpox vaccine against monkeypox.
Bavarian Nordic eyes European monkeypox approval for smallpox vaccine
Bavarian Nordic’s smallpox vaccine, Jynneos, hasn’t yet been approved for monkeypox in Europe, a fact that hasn’t stopped countries there from lining up to secure vaccine supplies in light of the recent outbreak.
New CFO wants to shake things up at WSA
A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.
Chinese patent expiration dates draw closer for Novo Nordisk
In coming years, Novo Nordisk will take blows in the shape of several patents terminating on the second-biggest market for the firm, a Danish media reports.
Nordic Medical Affairs Manager 
Senior Manager, Clinical Trial Budget 
Production Director 
Industrial Designer- Design Engineer 
Clinical Project Manager 
Quality System Manager 
Analytical Coordinator for Analytical Development 
SAP System Specialist (Product Supply) – Business Application Services 
Senior Chemical Safety Advisor 
Account Manager 
System Sales Development Consultant - Investment Projects, Merck Millipore 
(Senior) Drug Substance Specialist 
Senior Project Manager (GMP - Life Science) 
Clinical Trial Manager for development of in vitro diagnostics 
Key Account Manager, Europe and Asia 
Director for innovative pre-clinical testing unit 
Communications Consultant